Key facts
- Path Ex’s last known valuation is $31.0M (Apr 2025).
- It has raised $12.5M across 1 recorded rounds; the latest was Early Stage VC ($8.2M) in Apr 2025.
- Notable investors include US National Science Foundation, MassChallenge, MedTech Innovator, Texas Medical Center, Johnson & Johnson Innovation - JLABS — 18 tracked in total.
- Path Ex has filed 1 Form D with the SEC, most recently May 2025 ($8.2M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Path Ex
Funding rounds
1 roundsAbout Path Ex
Developer of an extracorporeal blood-cleansing device designed for the diagnosis and treatment of sepsis. The company's device selectively removes pathogens, including multidrug-resistant bacteria and endotoxin from circulating blood, enabling health professionals to eliminate intact bacteria from the blood rather than trying to kill the infection.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2017
- Employees
- 7
- Website
- pathex.co/
- Ownership
- Privately Held (backing)
Path Ex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Path Ex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Path Ex in its N-PORT filings yet. We sweep new filings monthly.